Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26129093 | 0.91 | AGTR2 (0.51) | AGTR2CYP3A4 | |
| SCHEMBL26127611 | 0.91 | AGTR2 (0.55) | AGTR2CYP3A4 | |
| SCHEMBL26129333 | 0.90 | AGTR2 (0.46) | AGTR2CYP3A4 | |
| SCHEMBL30613499 | 0.89 | AGTR2 (0.43) | AGTR2CYP3A4 | |
| SCHEMBL26126548 | 0.89 | AGTR2 (0.43) | AGTR2CYP3A4 | |
| SCHEMBL25246111 | 0.88 | AGTR2 (0.47) | AGTR2CYP3A4 | |
| SCHEMBL31476809 | 0.87 | AGTR2 (0.56) | AGTR2CYP3A4 | |
| SCHEMBL26129202 | 0.87 | AGTR2 (0.56) | AGTR2CYP3A4 | |
| SCHEMBL26129204 | 0.86 | AGTR2 (0.48) | AGTR2CYP3A4 | |
| SCHEMBL26129143 | 0.84 | AGTR2 (0.56) | AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214978-A1 | AT2R AGONIST | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-07-03 | — | — | US | disclosed |
| EP-4506345-A1 | AT2R AGONIST | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-02-12 | — | — | EP | disclosed |
| CN-116891464-A | AT2R agonist | 武汉人福创新药物研发中心有限公司 | 2023-10-17 | — | — | CN | disclosed |
| WO-2023193733-A1 | AT2R AGONIST | 武汉人福创新药物研发中心有限公司 | 2023-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214978-A1 | AT2R AGONIST | AGTR1, AGTR2, AVPR2 | AGTR2 2/4885CYP3A4 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.